Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis

Background The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2020-06, Vol.23 (2), p.220-231
Main Authors: Guan, Yupeng, Xiong, Haiyun, Feng, Yupeng, Liao, Guolong, Tong, Tongyu, Pang, Jun
Format: Article
Language:English
Subjects:
631/67/589/466
692/53/2422
Analysis
Androstenes - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers
Biomarkers, Tumor - analysis
Biomedical and Life Sciences
Biomedicine
Blood Platelets - pathology
Cancer
Cancer patients
Cancer Research
Care and treatment
Castration
Clinical trials
Confidence intervals
Development and progression
Humans
Indicators
Inflammation
Lymphocytes
Lymphocytes - pathology
Male
Medical prognosis
Meta-analysis
Metastases
Metastasis
Neutrophils
Neutrophils - pathology
Oncology, Experimental
Phenylthiohydantoin - administration & dosage
Phenylthiohydantoin - analogs & derivatives
Platelets
Prognosis
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Quality assessment
Review Article
Search engines
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR. Methods Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS). Results A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43–1.85, P  
ISSN:1365-7852
1476-5608
DOI:10.1038/s41391-020-0209-3